Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin for diabetic foot ulcer inflammation and healing
ACTRN12613000418774Phase 4Recruiting
- Sponsor
- Assoc. Professor Usman H. Malabu; FRCPI, FRACP.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in diabetic foot ulcer (DFU) and type 2 diabetes mellitus (T2DM) comparing Metformin + vildagliptin with Metformin + placebo (2 arms). Primary endpoint: Reduction in serum interleukin-6. Started May 2014; status: recruiting.
02
Drugs
vildagliptin
03
Conditions
diabetic foot ulcer (DFU)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12613000418774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000418774.